Active Ingredient History
Saccharomyces boulardii is a tropical yeast first isolated from lychee and mangosteen fruit peel in 1923 by French scientist Henri Boulard. Although early reports claimed distinct taxonomic, metabolic, and genetic properties, S. boulardii is genetically a grouping of S. cerevisiae strains, sharing >99% genomic relatedness, giving the synonym S. cerevisiae var. boulardii. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anti-Bacterial Agents (Phase 4)
Chronic Periodontitis (Phase 1/Phase 2)
Clostridioides difficile (Phase 3)
Colorectal Neoplasms (Phase 4)
Crohn Disease (Phase 1/Phase 2)
Diarrhea (Phase 4)
Drug Resistance, Bacterial (Phase 4)
Enterocolitis, Necrotizing (Phase 3)
Gastroenteritis (Phase 4)
Healthy Volunteers (Early Phase 1)
Heart Failure (Phase 2)
Heart Failure, Systolic (Phase 2)
Helicobacter pylori (Phase 4)
HIV Infections (Phase 2)
Hyperbilirubinemia (Phase 4)
Hyperoxaluria (Phase 1/Phase 2)
Infant, Premature, Diseases (Phase 3)
Infections (Phase 4)
Intestinal Neoplasms (Phase 4)
Irritable Bowel Syndrome (Phase 4)
Live Birth (Phase 4)
Liver Cirrhosis (Phase 2)
Nephrolithiasis (Phase 1/Phase 2)
Scleroderma, Systemic (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
